Systematic review and meta-analysis of randomized trials of central nervous system directed therapy for childhood acute lymphoblastic leukemia

Pediatric Blood and Cancer

Volumn 60, Issue 2, 2013, Pages 185-195

  Richards, Sue ^a   Pui, Ching Hon ^b   Gayon, Paul ^c  

^a UNIVERSITY OF OXFORD   (United Kingdom)

^b ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

^c CHILDREN S HOSPITAL LOS ANGELES   (United States)

Author keywords

Childhood leukemia; CNS; Leukemia; Meta analysis; Triple intrathecal therapy

Indexed keywords

CYTARABINE; DEXAMETHASONE; FOLINIC ACID; HYDROCORTISONE; MERCAPTOPURINE; METHOTREXATE; PREDNISONE;

ACUTE LYMPHOBLASTIC LEUKEMIA; CANCER RADIOTHERAPY; CANCER SURVIVAL; CENTRAL NERVOUS SYSTEM; CHILDHOOD LEUKEMIA; DRUG MEGADOSE; EVENT FREE SURVIVAL; HUMAN; MEDLINE; META ANALYSIS; MULTIPLE CYCLE TREATMENT; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SKULL IRRADIATION; SYSTEMATIC REVIEW;

ANTINEOPLASTIC AGENTS; CENTRAL NERVOUS SYSTEM; CENTRAL NERVOUS SYSTEM NEOPLASMS; CHILD; HUMANS; INJECTIONS, SPINAL; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 84865165714     PISSN: 15455009     EISSN: 15455017     Source Type: Journal    
DOI: 10.1002/pbc.24228     Document Type: Review

References (62)

1. Pui CH, Howard SC. Current management and challenges of malignant disease in the CNS in paediatric leukaemia. Lancet Oncol 2008; 9: 57-68.
2. Mody R, Li S, Dover DC, et al. Twenty-five-year follow-up among survivors of childhood acute lymphoblastic leukemia: A report from the childhood cancer survivor study. Blood 2008; 111: 5515-5523.
3. Veerman AJ, Kamps WA, van den Berg H, et al. Dexamethasone-based therapy for childhood acute lymphoblastic leukaemia: Results of the prospective dutch childhood oncology group (DCOG) protocol ALL-9(1997-2004). Lancet Oncol 2009; 10: 957-966.
4. Pui CH, Campana D, Pei D, et al. Treating childhood acute lymphoblastic leukemia without cranial irradiation. N Engl J Med 2009; 360: 2730-2741.
5. Clarke M, Gaynon P, Hann I, et al. CNS-directed therapy for childhood acute lymphoblastic leukemia: Childhood ALL collaborative group overview of 43 randomized trials. J Clin Oncol 2003; 21: 1798-1809.
6. Bostrom BC, Sensel MR, Sather HN, et al. Dexamethasone versus prednisone and daily oral versus weekly intravenous mercaptopurine for patients with standard-risk acute lymphoblastic leukemia: A report from the children's cancer group. Blood 2003; 101: 3809-3817.
7. Mitchell CD, Richards SM, Kinsey SE, et al. Benefit of dexamethasone compared with prednisolone for childhood acute lymphoblastic leukaemia: Results of the UK Medical Research Council ALL97 randomized trial. Br J Haematol 2005; 129: 734-745.
8. Inaba H, Pui CH. Glucocorticoid use in acute lymphoblastic leukaemia. Lancet Oncol 2010; 11: 1096-1106.
9. Escherich G, Richards S, Stork LC, et al. Meta-analysis of randomised trials comparing thiopurines in childhood acute lymphoblastic leukaemia. Leukemia 2011; 25: 953-959.
10. Early Breast Cancer Trialists' Collaborative Group. Treatment of Early Breast Cancer. Volume 1: Worldwide Evidence 1985-1990. Oxford, UK: Oxford University Press; 1990. 207 pp.
11. Matloub Y, Lindemulder S, Gaynon PS, et al. Intrathecal triple therapy decreases central nervous system relapse but fails to improve event-free survival when compared with intrathecal methotrexate: Results of the children's cancer group (CCG) 1952 study for standard-risk acute lymphoblastic leukemia, reported by the children's oncology group. Blood 2006; 108: 1165-1173.
12. Littman P, Coccia P, Bleyer WA, et al. Central nervous system (CNS) prophylaxis in children with low risk acute lymphoblastic leukemia (ALL). Int J Radiat Oncol Biol Phys 1987; 13: 1443-1449.
13. Tubergen DG, Gilchrist GS, O'Brien RT, et al. Prevention of CNS disease in intermediate-risk acute lymphoblastic leukemia: Comparison of cranial radiation and intrathecal methotrexate and the importance of systemic therapy: A childrens cancer group report. J Clin Oncol 1993; 11: 520-526.
14. Nachman J, Sather HN, Cherlow JM, et al. Response of children with high-risk acute lymphoblastic leukemia treated with and without cranial irradiation: A report from the children's cancer group. J Clin Oncol 1998; 16: 920-930.
15. van Eys J, Berry D, Crist W, et al. A comparison of two regimens for high-risk acute lymphocytic leukemia in childhood. A pediatric oncology group study. Cancer 1989; 63: 23-29.
16. Ortega JJ, Javier G, Olive T. Treatment of standard- and high-risk childhood acute lymphoblastic leukaemia with two CNS prophylaxis regimens. Haematol Blood Transfus 1987; 30: 483-492.
17. Stark B, Nirel R, Avrahami G, et al. Long-term results of the Israeli national studies in childhood acute lymphoblastic leukemia: INS 84, 89 and 98. Leukemia 2010; 24: 419-424.
18. Moghrabi A, Levy DE, Asselin B, et al. Results of the Dana-Farber cancer institute ALL consortium protocol 95-01 for children with acute lymphoblastic leukemia. Blood 2007; 109: 896-904.
19. Masson E, Relling MV, Synold TW, et al. Accumulation of methotrexate polyglutamates in lymphoblasts is a determinant of antileukemic effects in vivo. A rationale for high-dose methotrexate. J Clin Invest 1996; 97: 73-80.
20. Mahoney DHJ, Shuster JJ, Nitschke R, et al. Acute neurotoxicity in children with B-precursor acute lymphoid leukemia: An association with intermediate-dose intravenous methotrexate and intrathecal triple therapy-A pediatric oncology group study. J Clin Oncol 1998; 16: 1712-1722.
21. Schaison GS, Baruchel A, Leblanc TAM, et al. Therapy of childhood acute lymphoblastic leukemia. Int J Pediatr Hematol Oncol 1998; 5: 145-154.
22. Pui CH, Sandlund JT, Pei D, et al. Improved outcome for children with acute lymphoblastic leukemia: Results of total therapy study XIIIB at St. Jude children's research hospital. Blood 2004; 104: 2690-2696.
23. Lange BJ, Blatt J, Sather HN, et al. Randomized comparison of moderate-dose methotrexate infusions to oral methotrexate in children with intermediate risk acute lymphoblastic leukemia: A childrens cancer group study. Med Pediatr Oncol 1996; 27: 15-20.
24. LeClerc JM, Billett AL, Gelber RD, et al. Treatment of childhood acute lymphoblastic leukemia: Results of Dana-Farber ALL consortium protocol 87-01. J Clin Oncol 2002; 20: 237-246.
25. Hill FG, Richards S, Gibson B, et al. Successful treatment without cranial radiotherapy of children receiving intensified chemotherapy for acute lymphoblastic leukaemia: Results of the risk-stratified randomized central nervous system treatment trial MRC UKALL XI (ISRC TN 16757172). Br J Haematol 2004; 124: 33-46.
26. Niemeyer CM, Reiter A, Riehm H, et al. Comparative results of two intensive treatment programs for childhood acute lymphoblastic leukemia: The Berlin-Frankfurt-Munster and Dana-Farber cancer institute protocols. Ann Oncol 1991; 2: 745-749.
27. Asselin BL, Devidas M, Wang C, et al. Effectiveness of high-dose methotrexate in T-cell lymphoblastic leukemia and advanced-stage lymphoblastic lymphoma: A randomized study by the children's oncology group (POG 9404). Blood 2011; 118: 874-883.
28. Pullen J, Boyett J, Shuster J, et al. Extended triple intrathecal chemotherapy trial for prevention of CNS relapse in good-risk and poor-risk patients with B-progenitor acute lymphoblastic leukemia: A pediatric oncology group study. J Clin Oncol 1993; 11: 839-849.
29. Henderson ES, Scharlau C, Cooper MR, et al. Combination chemotherapy and radiotherapy for acute lymphocytic leukemia in adults: Results of CALGB protocol 7113. Leuk Res 1979; 3: 395-407.
30. Bleyer WA. Intrathecal methotrexate versus central nervous system leukemia. Cancer Drug Deliv 1984; 1: 157-167.
31. Medical Research Council leukaemia trial, UKALL VII. A report to the Council by the Working Party on Leukaemia in Childhood Arch Dis Child 1985; 60: 1050-1054.
32. Freeman AI, Boyett JM, Glicksman AS, et al. Intermediate-dose methotrexate versus cranial irradiation in childhood acute lymphoblastic leukemia: A ten-year follow-up. Med Pediatr Oncol 1997; 28: 98-107.
33. Poplack DG, Reaman GH, Bleyer WA, et al. CNS preventive therapy with high-dose methotrexate in acute lymphoblastic leukemia: A preliminary report. Proc Am Soc Clin Oncol 1984; 3: abstr 797.
34. Moricke A, Zimmermann M, Reiter A, et al. Long-term results of five consecutive trials in childhood acute lymphoblastic leukemia performed by the ALL-BFM study group from 1981 to 2000. Leukemia 2010; 24: 265-284.
35. Zintl F, Plenert W, Malke H. Results of acute lymphoblastic leukemia therapy in childhood with a modified BFM protocol in a multicenter study in the German democratic republic. Haematol Blood Transfus 1987; 30: 471-479.
36. Tsurusawa M, Katano N, Yamamoto Y, et al. Improvement in CNS protective treatment in non-high-risk childhood acute lymphoblastic leukemia: Report from the Japanese children's cancer and leukemia study group. Med Pediatr Oncol 1999; 32: 259-266.
37. Viana MB, Murao M, Ramos G, et al. Malnutrition as a prognostic factor in lymphoblastic leukaemia: A multivariate analysis. Arch Dis Child 1994; 71: 304-310.
38. Tsuchida M, Ohara A, Manabe A, et al. Long-term results of Tokyo children's cancer study group trials for childhood acute lymphoblastic leukemia, 1984-1999. Leukemia 2010; 24: 383-396.
39. Hann I, Vora A, Richards S, et al. Benefit of intensified treatment for all children with acute lymphoblastic leukaemia: Results from MRC UKALL XI and MRC ALL97 randomised trials. UK medical research council's working party on childhood leukaemia. Leukemia 2000; 14: 356-363.
40. Salzer WL, Devidas M, Carroll WL, et al. Long-term results of the pediatric oncology group studies for childhood acute lymphoblastic leukemia 1984-2001: A report from the children's oncology group. Leukemia 2010; 24: 355-370.
41. Chessells JM, Durrant J, Hardy RM, et al. Medical research council leukaemia trial-UKALL V: An attempt to reduce the immunosuppressive effects of therapy in childhood acute lymphoblastic leukemia. Report to the council by the working party on leukaemia in childhood. J Clin Oncol 1986; 4: 1758-1764.
42. Eden OB, Lilleyman JS, Richards S. Testicular irradiation in childhood lymphoblastic leukaemia. Medical research council working party on leukemia in childhoods. Br J Haematol 1990; 75: 496-498.
43. Brandalise S, Odone V, Pereira W, et al. Treatment results of three consecutive Brazilian cooperative childhood ALL protocols: GBTLI-80, GBTLI-82 and -85. ALL Brazilian group. Leukemia 1993; 7: S142-S145.
44. Tsuchida M, Akatsuka J, Bessho F, et al. Treatment of acute lymphoblastic leukemia in the Tokyo children's cancer study group-Preliminary results of L84-11 protocol. Acta Paediatr Jpn 1991; 33: 522-532.
45. Duttera MJ, Bleyer WA, Pomeroy TC, et al. Irradiation, methotrexate toxicity, and the treatment of meningeal leukaemia. Lancet 1973; 2: 703-707.
46. Jones B, Freeman AI, Shuster JJ, et al. Lower incidence of meningeal leukemia when prednisone is replaced by dexamethasone in the treatment of acute lymphocytic leukemia. Med Pediatr Oncol 1991; 19: 269-275.
47. Komp DM, Fernandez CH, Falletta JM, et al. CNS prophylaxis in acute lymphoblastic leukemia: Comparison of two methods a Southwest oncology group study. Cancer 1982; 50: 1031-1036.
48. Dritschilo A, Cassady JR, Camitta B, et al. The role of irradiation in central nervous system treatment and prophylaxis for acute lymphoblastic leukemia. Cancer 1976; 37: 2729-2735.
49. Brecher ML, Berger P, Freeman AI, et al. Computerized tomography scan findings in children with acute lymphocytic leukemia treated with three different methods of central nervous system prophylaxis. Cancer 1985; 56: 2430-2433.
50. Ortega JA, Nesbit ME, Sather HN, et al. Long-term evaluation of a CNS prophylaxis trial-treatment comparisons and outcome after CNS relapse in childhood ALL: A report from the childrens cancer study group. J Clin Oncol 1987; 5: 1646-1654.
51. Steinherz PG, Gaynon PS, Breneman JC, et al. Treatment of patients with acute lymphoblastic leukemia with bulky extramedullary disease and T-cell phenotype or other poor prognostic features: Randomized controlled trial from the children's cancer group. Cancer 1998; 82: 600-612.
52. Vilmer E, Suciu S, Ferster A, et al. Long-term results of three randomized trials (58831, 58832, 58881) in childhood acute lymphoblastic leukemia: A CLCG-EORTC report. children leukemia cooperative group. Leukemia 2000; 14: 2257-2266.
53. Donadieu J, Auclerc MF, Baruchel A, et al. Critical study of prognostic factors in childhood acute lymphoblastic leukaemia: Differences in outcome are poorly explained by the most significant prognostic variables. Fralle group. French acute lymphoblastic leukaemia study group. Br J Haematol 1998; 102: 729-739.
54. Holland JF, Glidewell O. Chemotherapy of acute lymphocytic leukemia of childhood. Cancer 1972; 30: 1480-1487.
55. Sackmann Muriel F, Pavlovsky S, Penalver JA, et al. Evaluation of induction of remission, intensification, and central nervous system prophylactic treatment in acute lymphoblastic leukemia. Cancer 1974; 34: 418-426.
56. Moss HA, Nannis ED, Poplack DG. The effects of prophylactic treatment of the central nervous system on the intellectual functioning of children with acute lymphocytic leukemia. Am J Med 1981; 71: 47-52.
57. Borsi JD, Wesenberg F, Stokland T, et al. How much is too much? Folinic acid rescue dose in children with acute lymphoblastic leukaemia. Eur J Cancer 1991; 27: 1006-1009.
58. Skarby TV, Anderson H, Heldrup J, et al. High leucovorin doses during high-dose methotrexate treatment may reduce the cure rate in childhood acute lymphoblastic leukemia. Leukemia 2006; 20: 1955-1962.
59. Matloub Y, Bostrom BC, Hunger SP, et al. Escalating intravenous methotrexate improves event-free survival in children with standard-risk acute lymphoblastic leukemia: A report from the children's oncology group. Blood 2011; 118: 243-251.
60. Winick NJ, Salzer WL, Devidas M, et al. Dexamethasone (DEX) versus prednisone (PRED) during induction for children with high-risk acute lymphoblastic leukemia (HR-ALL): A report from the children's onocology group study AALL0232. J Clin Oncol 2011; 29: abstr 9504.
61. Larsen EC, Salzer WL, Devidas M, et al. Comparison of high-dose methotrexate (HD-MTX) with Capizzi methotrexate plus asparaginse (C-MTX/ASNase) in children and young adults with high-risk acute lymphoblastic leukemia (HR-ALL): A report from the children's oncology group study AALL0232. J Clin Oncol 2011; 29: abstr 3.
62. Nathan PC, Whitcomb T, Wolters PL, et al. Very high-dose methotrexate (33.6g/m(2)) as central nervous system preventive therapy for childhood acute lymphoblastic leukemia: Results of national cancer institute/children's cancer group trials CCG-191P, CCG-134P and CCG-144P. Leuk Lymphoma 2006; 47: 2488-2504.